Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Decheng Capital LLC
Form 13F · Q2 2026

Decheng Capital LLC

CIK 2010850Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$732M
Reported book value
14
Positions
11
Quarters on record
Top 50
Positions

Decheng Capital LLC — holdings

Top 14 positions of 14, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1CGON Cg Oncology Inc6.4M+0.0%$453M61.9%
2NUVB Nuvation Bio Inc26.0M+0.0%$147M20.1%
3AARD Aardvark Therapeutics Inc3.9M+0.0%$23M3.1%
4ACRS Aclaris Therapeutics Inc4.0M+0.0%$21M2.9%
5UPB Upstream Bio Inc2.7M+0.0%$19M2.6%
6RCUS Arcus Biosciences Inc464,779−2.7%$14M2.0%
7EQ Equillium Inc4.4M+0.0%$14M1.9%
8RVMD Revolution Medicines Inc52,667−43.7%$10M1.3%
9LYEL Lyell Immunopharma, Inc.692,050+0.0%$10M1.3%
10BYSI BeyondSpring Inc.3.8M+0.0%$7M0.9%
11ZNTL Zentalis Pharmaceuticals Inc1.3M+0.0%$6M0.9%
12NAMS Newamsterdam Pharma Company176,887−45.6%$6M0.8%
13PYXS Pyxis Oncology Inc326,810+0.0%$983,6980.1%
14TNGX Tango Therapeutics Inc20,000—$625,2000.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.